intravenous and subcutaneous epidural and mucosal e g intranasal and oral routes the pharmaceutical compositions of the anti rsv agents may be administered by any convenient route for example by infusion or bolus injection by absorption through epithelial or mucocutaneous linings e g oral mucosa rectal and intestinal mucosa etc and may be administered together with other biologically active agents administration can be systemic or local in addition pulmonary administration can also be employed e g by use of an inhaler or nebulizer and formulation with an aerosolizing agent the compositions and pharmaceutical compositions may be administered locally to the area in need of treatment this may be achieved by for example local infusion by injection or by means of an implant the implant being of a porous non porous or gelatinous material including membranes such as sialastic membranes or fibers the compositions and pharmaceutical compositions of the invention can be delivered in a controlled release or sustained release system for example a pump may be used to achieve controlled or sustained release polymeric materials can be used to achieve controlled or sustained release examples of polymers used in sustained release formulations include but are not limited to poly 2 hydroxy ethyl methacrylate poly methyl methacrylate poly acrylic acid poly ethylene co vinyl acetate poly methacrylic acid polyglycolides plg polyanhydrides poly n vinyl pyrrolidone poly vinyl alcohol polyacrylamide.